Reform Pharma plc

July 01, 2009 08:33 ET

Change of Corporate Adviser & Director

                                      CHANGE OF CORPORATE ADVISER

                                    Change of Non Executive Director

The  Board  of  Reform Pharma plc (the 'Company') is pleased to announce that it has  appointed  First
London  Securities Limited ('First London') as its corporate adviser to replace St Helen's  Capital  Plc
('St Helen's Capital') effective 1st July, 2009.

St  Helen's  Capital  has advised the Company since listing and has agreed to resign  on  an  entirely
amicable basis. The Directors of Reform Pharma are grateful for the support of St Helen's Capital.

The Company looks forward to a mutually profitable relationship with First London.

As a result of this change in Corporate Adviser, Andrew Turner, a Non Executive Director, has resigned
as a Director of Reform Pharma, and Roger Ashby has been appointed as Non Executive Director.

Roger  has  had  a  diversified career in the energy and electronics and holds an  honours  degree  in
metallurgy from the University of Leeds along with post graduate diplomas from Cambridge and the Welsh
School  of  Management.  His career started in the oil industry with Royal Dutch  Shell  working  post
exploration  facilities  both for oil and LNG in the Middle East, Africa and  North  Sea.  He  founded
Satellite  Technologies Systems Ltd in 1985 being one of the first retail communications companies  in
Europe. The company became European partner for Satcom Inc producing a range of OEM telephone, fax and
imaging  products. Upon the opening of the Soviet Union he became CEO of MTM House  Ltd  a  specialist
trader in Russian copper to the London Metal Exchange with the responsibility to supply communications
equipment into Russia with the arising proceeds. In 1994 he was a founding Director of Dove Energy Ltd
which  managed the oil assets of Neste Oy in several North Sea fields and progressed to  take  onshore
licences  in the Yemen and Syria. The company specialised in using innovative technologies to increase
reservoir  yields. Latterly he was recruited by The Gatsby Trust to advise universities on  technology
transfer  and  was  responsible  for the establishment of the £100m University  Challenge  Seed  Fund.
Arising from his work with the universities he was a founding director of Kymata  Ltd., a fibre optic 
grating manufacturer, which exited by trade sale for $600m after 4  years.He is a member of the International Licensing Executives Society, UNICO, AUTM and The R & D Society.

Roger  is  currently  a  Director  of the following companies, Organotech  Limited,  Nolah
Innovations  Limited,  Stemcell  Ventures  Limited, Auxetix Limited,  Ostco  Limited,  Zetco  Limited,
Castlico  Limited,  ICyte  Limited, Oncoyork Limited, Biopraxis Ltd, Upright Imaging  PLC,  Ophthaltec
Limited, Formformform Ltd, Nexstrata Resources PLC and Prize Mobile Group plc.

There has been no change to Directors holdings.

The Directors of Reform Pharma plc accept responsibility for this announcement.


Company              :          Mike O'Driscoll, CEO
                                Reform Pharma Plc
                                Norfolk House
                                31 St James's Square
                                London SW1Y 4JR
                                Telephone +44 (0)20 7451 3790

Corporate Adviser    :          Andrew Turner
                                First London Securities Limited
                                Norfolk House
                                31 St James's Square
                                London SW1Y 4JR
                                Telephone: +44 (0)20 7451 2490

Contact Information

  • Reform Pharma plc